(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Clinical trial NCT00768300 · TERMINATED

Trial details

NCT number: NCT00768300
Sponsor: Gilead Sciences
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

Start date: 2008-12-01
Primary completion: 2011-02-01
Enrollment: 494

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.